- Home
- ALXO vs GNTA Comparison
ALXO vs GNTA Comparison
Compare ALXO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | GNTA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 34.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | GNTA |
|---|---|---|
| Price | $2.15 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.42 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 124.6K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.71 |
| 52 Week High | $2.66 | $10.00 |
Technical Indicators
Market Signals| Indicator | ALXO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 44.16 |
| Support Level | $1.41 | $0.71 |
| Resistance Level | $2.27 | $1.70 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 23.08 | 58.33 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.